Lenalidomide Olainfarm

Lenalidomide, the active ingredient in Lenalidomide Olainfarm, is an immunomodulatory drug presented as an oral formulation for oral use. It is indicated for the treatment of multiple myeloma, mantle cell lymphoma, and myelodysplastic syndromes with deletion 5q, typically in adult patients who have received prior therapy.

GNH USA supplies Lenalidomide Olainfarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for import.

Lenalidomide Olainfarm is employed in hematologic malignancies and related disorders where immunomodulation and anti‑angiogenic activity are therapeutic goals.

- Multiple Myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease. - Mantle Cell Lymphoma: contributes to disease control when combined with other agents in relapsed settings. - Myelodysplastic Syndromes with del(5q): induces transfusion independence and cytogenetic remission in eligible patients.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet levels leading to bruising. - Anemia: decreased red blood cells causing weakness. - Diarrhea: loose stools that may require supportive care. - Rash: mild skin eruptions.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia or thrombocytopenia: profound marrow suppression. - Secondary primary malignancies: emergence of new cancers. - Severe liver injury: marked elevation of hepatic enzymes. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: life‑threatening skin reactions.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for known risks.

- Monitor blood counts: perform regular CBCs to detect cytopenias. - Assess thromboembolic risk: consider prophylactic anticoagulation in high‑risk patients. - Contraindicated in pregnancy: enforce strict contraception for both sexes. - Adjust for renal impairment: dose modifications may be required based on creatinine clearance. - Avoid live vaccines: immunosuppression can reduce vaccine efficacy. - Store at below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Lenalidomide can interact with several drug classes, necessitating careful review of concomitant medications.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce lenalidomide exposure and efficacy. - Live vaccines: increased risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., aspirin, clopidogrel): may heighten bleeding tendency. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): potential additive renal toxicity. - Other immunomodulatory agents (e.g., pomalidomide, thalidomide): can cause additive myelosuppression.